BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30636579)

  • 21. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
    Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells.
    Maehara N; Matsumoto K; Kuba K; Mizumoto K; Tanaka M; Nakamura T
    Br J Cancer; 2001 Mar; 84(6):864-73. PubMed ID: 11259105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.
    Nan L; Qin T; Xiao Y; Qian W; Li J; Wang Z; Ma J; Ma Q; Wu Z
    Cell Transplant; 2019; 28(9-10):1289-1298. PubMed ID: 31161784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.
    Kim HJ
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
    IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production.
    Qian LW; Mizumoto K; Maehara N; Ohuchida K; Inadome N; Saimura M; Nagai E; Matsumoto K; Nakamura T; Tanaka M
    Cancer Lett; 2003 Feb; 190(1):105-12. PubMed ID: 12536083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.
    Cui J; Xia T; Xie D; Gao Y; Jia Z; Wei D; Wang L; Huang S; Quan M; Xie K
    Oncogene; 2016 Sep; 35(36):4708-18. PubMed ID: 26876216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.
    Modica C; Tortarolo D; Comoglio PM; Basilico C; Vigna E
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
    Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
    Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
    J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
    Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
    Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of biological study for met expression to cancer therapy.
    Osada S; Yoshida K
    Anticancer Agents Med Chem; 2010 Jan; 10(1):58-63. PubMed ID: 20015003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
    Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
    J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.